Potential antiosteoporosis effect of biodegradable magnesium implanted in STZ‐induced diabetic rats
Source abstract
Abstract
Abstract Pure magnesium (Mg) was implanted intramedullary into the femur of streptozotocin (STZ)‐induced diabetic rats to investigate its effect on bone growth after 6 weeks degradation. The experimental results showed that the femoral BMD in diabetic rats was significantly lower than that in controls (p < 0.01) but restored notably by Mg implantation. The contents of calcium (Ca), phosphorus (P), Mg, zinc (Zn), potassium (K), strontium (Sr), and sulfur (S) in bone of diabetic group were significantly lower than those in controls but remarkably increased with implantation of Mg. The residual weight calculation showed that 29.41% of Mg was degraded in vivo. The energy dispersive X‐ray spectroscopy (EDS) analysis showed that the reaction layer on the surface of the Mg implant mainly consisted of C, Ca, O, P, and Mg. Besides, serum Mg level was significantly decreased in diabetic group compared with the control group but increased by Mg treatment. Also, there were no significant differences in body weight and blood glucose, as well as blood glycosylated hemoglobin (HbAIc%), serum Ca, alanine aminitransperase (ALT), aspartate aminotransferase (AST), uric acid (UA), nonesterified fatty acid (NEFA), cholinesterase (CHE), and creatinine (CR) levels between diabetic and Mg‐implanted rats. The study indicated that Mg implant had no obvious toxicity in STZ‐induced diabetic rats and may act as a potential agent to treat osteoporosis. © 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part A:, 2011.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Magnesium in Health and Disease · Magnesium Alloys: Properties and Applications · Parathyroid Disorders and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (42)
Show source-provided references
1. 10.1152/japplphysiol.00564.200310.1152/japplphysiol.00564.2003 ↗
2. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four‐year results from a randomized clinical trial10.1210/jcem.87.8.8750 ↗
3. 10.1007/s12011-007-8043-110.1007/s12011-007-8043-1 ↗
4. 10.2337/diaclin.22.1.1010.2337/diaclin.22.1.10 ↗
5. Metal degradation products: A cause for concern in metal‐metal bearings?10.1097/01.blo.0000096810.78689.62 ↗
6. 10.1023/A:101797971099210.1023/A:1017979710992 ↗
7. 10.1016/S0142-9612(99)00235-510.1016/S0142-9612(99)00235-5 ↗
8. 10.1007/s10856-007-3172-910.1007/s10856-007-3172-9 ↗
9. 10.1002/jbm.a.3127310.1002/jbm.a.31273 ↗
10. 10.1016/j.biomaterials.2004.09.04910.1016/j.biomaterials.2004.09.049 ↗
11. 10.1016/j.biomaterials.2005.07.03710.1016/j.biomaterials.2005.07.037 ↗
12. 10.1002/jbm.a.3129310.1002/jbm.a.31293 ↗
13. 10.1016/j.biomaterials.2007.12.02110.1016/j.biomaterials.2007.12.021 ↗
14. 10.1016/j.actbio.2009.06.02810.1016/j.actbio.2009.06.028 ↗
15. 10.1088/1748-6041/5/4/04500510.1088/1748-6041/5/4/045005 ↗
16. 10.1023/A:101605822997210.1023/A:1016058229972 ↗
17. 10.1016/S0098-2997(02)00087-010.1016/S0098-2997(02)00087-0 ↗
18. 10.1023/A:101602273088010.1023/A:1016022730880 ↗
19. 10.1007/s11255-009-9548-710.1007/s11255-009-9548-7 ↗
20. 10.1016/j.jnutbio.2004.08.00110.1016/j.jnutbio.2004.08.001 ↗
21. 10.3177/jnsv.50.1910.3177/jnsv.50.19 ↗
22. 10.1007/s12011-009-8416-810.1007/s12011-009-8416-8 ↗
23. 10.1507/endocrj.K07-04010.1507/endocrj.K07-040 ↗
24. 10.1007/s00198-006-0104-310.1007/s00198-006-0104-3 ↗
25. 10.1681/ASN.200801009810.1681/ASN.2008010098 ↗
26. Effect of dietary magnesium supplementation on bone loss in rats fed a high phosphorus diet
27. 10.1016/j.ejim.2004.01.00310.1016/j.ejim.2004.01.003 ↗
28. Magnesium directly stimulates osteoblast proliferation
29. 10.2116/analsci.16.116110.2116/analsci.16.1161 ↗
30. 10.2116/bunsekikagaku.47.83510.2116/bunsekikagaku.47.835 ↗
31. 10.1080/07315724.2009.1071976410.1080/07315724.2009.10719764 ↗
32. 10.1080/07315724.2000.1071807010.1080/07315724.2000.10718070 ↗
33. The influence of calcium and phosphorus intake on bone mineral density in young women
34. 10.1007/s00223-002-1093-710.1007/s00223-002-1093-7 ↗
35. Calcium, magnesium, and potassium as dietary nutrients
36. 10.1016/S0169-6009(08)80122-510.1016/S0169-6009(08)80122-5 ↗
37. Usual dietary magnesium intake in NHANES III is associated with femoral bone mass
38. Phosphorus intake and bone mineral density (BMD)
39. 10.1007/BF0092573710.1007/BF00925737 ↗
40. 10.1016/j.coph.2005.05.00510.1016/j.coph.2005.05.005 ↗
41. 10.1016/j.jssc.2003.09.01210.1016/j.jssc.2003.09.012 ↗
42. 10.1016/j.surfcoat.2003.10.06110.1016/j.surfcoat.2003.10.061 ↗